MD Anderson and Lion Biotechnologies announce strategic alliance to conduct clinical trials of TILs

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news